This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (61)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Alert me on articles by topic  Social Bookmarking   What's this?

Olaf Stüve, MD; Sabine Cepok, PhD; Birte Elias, MD; Andreas Saleh, MD; Hans-Peter Hartung, MD; Bernhard Hemmer, MD; Bernd C. Kieseier, MD

Arch Neurol. 2005;62:1620-1623.

Background  The anti-CD20 monoclonal antibody rituximab effectively depletes B lymphocytes and has been successfully used in the therapy of immune-mediated disorders of the peripheral nervous system. A limited effect of rituximab on B lymphocytes in the cerebrospinal fluid compartment of patients with primary progressive multiple sclerosis (MS) was recently reported.

Objective  To determine the effect of rituximab on clinical, magnetic resonance imaging, and immunological variables in a patient with relapsing-remitting MS.

Design  A patient with relapsing-remitting MS was treated with rituximab. The patient was repeatedly examined clinically and by magnetic resonance imaging. The frequency of peripheral blood and cerebrospinal fluid B lymphocytes was assessed by flow cytometry before, during, and after rituximab therapy.

Results  Rituximab monotherapy resulted in significant clinical improvement. Inflammatory surrogate markers on magnetic resonance imaging were also reduced. B lymphocytes were depleted in the cerebrospinal fluid and peripheral blood.

Conclusions  Our data demonstrate beneficial clinical effects of rituximab in relapsing-remitting MS, mediated through modulation of humoral systemic and central nervous system intrinsic immune responses. Clinical trials should determine optimal therapeutic strategies for patients with relapsing-remitting MS.

Author Affiliations: Department of Neurology (Drs Stüve, Cepok, Elias, Hartung, Hemmer, and Kieseier) and Institute of Diagnostic Radiology (Dr Saleh), Heinrich-Heine University, Düsseldorf, Germany; and Department of Neurology, University of Texas Southwestern Medical Center at Dallas (Dr Stüve).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Effective Suppression of Cerebrospinal Fluid B Cells by Rituximab and Cyclophosphamide in Progressive Multiple Sclerosis
Hela-F Petereit and Andrea Rubbert
Arch Neurol. 2005;62(10):1641-1642.
EXTRACT | FULL TEXT  

Effective Suppression of Cerebrospinal Fluid B Cells by Rituximab and Cyclophosphamide in Progressive Multiple Sclerosis—Reply
Nancy L. Monson
Arch Neurol. 2005;62(10):1642.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Depletion of B Lymphocytes From Cerebral Perivascular Spaces by Rituximab
Martin et al.
Arch Neurol 2009;66:1016-1020.
ABSTRACT | FULL TEXT  

Antigen-Specific Blockade of Lethal CD8 T-Cell Mediated Autoimmunity in a Mouse Model of Multiple Sclerosis
Na et al.
J. Immunol. 2009;182:6569-6575.
ABSTRACT | FULL TEXT  

Long-term B-Lymphocyte Depletion With Rituximab in Patients With Relapsing-Remitting Multiple Sclerosis
Stuve et al.
Arch Neurol 2009;66:259-261.
ABSTRACT | FULL TEXT  

Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders
Petereit and Rubbert-Roth
Mult Scler 2009;15:189-192.
ABSTRACT  

Androgen depletion increases the efficacy of bone marrow transplantation in ameliorating experimental autoimmune encephalomyelitis
Barnard et al.
Blood 2009;113:204-213.
ABSTRACT | FULL TEXT  

Persistence of Immunopathological and Radiological Traits in Multiple Sclerosis
Konig et al.
Arch Neurol 2008;65:1527-1532.
ABSTRACT | FULL TEXT  

Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model
Borel et al.
Int Immunol 2008;20:1313-1319.
ABSTRACT | FULL TEXT  

Review: Innovative monoclonal antibody therapies in multiple sclerosis
Linker and Kieseier
Therapeutic Advances in Neurological Disorders 2008;1:33-42.
ABSTRACT  

Invited Article: Inhibition of B cell functions: Implications for neurology
Dalakas
Neurology 2008;70:2252-2260.
ABSTRACT | FULL TEXT  

Interferon-{beta} increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity
Krumbholz et al.
Brain 2008;131:1455-1463.
ABSTRACT | FULL TEXT  

Autoantibody Profiling in Multiple Sclerosis Reveals Novel Antigenic Candidates
Somers et al.
J. Immunol. 2008;180:3957-3963.
ABSTRACT | FULL TEXT  

Relapses After Treatment With Rituximab in a Patient With Multiple Sclerosis and Anti Myelin-Associated Glycoprotein Polyneuropathy
Benedetti et al.
Arch Neurol 2007;64:1531-1533.
ABSTRACT | FULL TEXT  

Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis
Duddy et al.
J. Immunol. 2007;178:6092-6099.
ABSTRACT | FULL TEXT  

Consensus statement on the use of rituximab in patients with rheumatoid arthritis
Smolen et al.
Ann Rheum Dis 2007;66:143-150.
ABSTRACT | FULL TEXT  

Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis
Zhou et al.
Proc. Natl. Acad. Sci. USA 2006;103:19057-19062.
ABSTRACT | FULL TEXT  

Effective Suppression of Cerebrospinal Fluid B Cells by Rituximab and Cyclophosphamide in Progressive Multiple Sclerosis--Reply
Monson
Arch Neurol 2005;62:1642-1642.
FULL TEXT